




Endeavor[®] Sprint

ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

ENDEAVOR IV and ENDEAVOR Pooled Analysis 5-Year Data

TCT 2011



ENDEAVOR IV and ENDEAVOR Pooled Results at 5 Years

ENDEAVOR IV

- **Statistically significant difference in safety event rates for Endeavor DES vs. Taxus[®] DES**
 - 78% significant relative risk reduction in ARC definite/probable VLST ($p = 0.012$)
 - 30% significant relative risk reduction in CD/MI ($p = 0.048$)
- **TLR catch-up with Taxus DES leads to similar TLR**
 - 161% Increase with Taxus DES vs. only 71% TLR Increase with Endeavor DES from 1 to 5 years

ENDEAVOR Pooled

- **Low ENDEAVOR Pooled composite and component event rates**

p-Values were calculated by logrank test.


ENDEAVOR IV primary endpoint: noninferiority of Endeavor DES to Taxus DES at 9 months (target vessel failure).

ENDEAVOR IV was not specifically designed or powered to individually compare TLR, CD/MI or VLST.

p-Values for outcome differences are unadjusted for multiple comparisons.

18% Observed Relative Risk Reduction in TVF


ENDEAVOR IV at 5 Years



p-Values were calculated by logrank test. *p*-Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV primary endpoint: noninferiority of Endeavor DES to Taxus DES at 9 months (target vessel failure). RRR = relative risk reduction

78% Significant Relative Risk Reduction in Very Late Stent Thrombosis


ENDEAVOR IV at 5 Years: ARC Definite/Probable ST



p -Values were calculated by logrank test. p -Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV was not specifically designed or powered to individually compare VLST. RRR = relative risk reduction

ENDEAVOR IV


Dual Antiplatelet Therapy Use to 5 Years



The optimal duration of dual antiplatelet therapy, specifically clopidogrel, is unknown and DES thrombosis may still occur despite continued therapy. DAPT usage based on case report forms and reported at the time points shown. Trend line is for illustrative purposes only and does not represent continuous reporting.

Late Catch up with Taxus DES

ENDEAVOR IV shows similar TLR rates at 5 years




161% Increase with Taxus DES vs. only 71% TLR Increase with Endeavor DES from 1 to 5 years

p-Value was calculated by logrank test. *p*-Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV was not specifically designed or powered to individually compare TLR.

Endeavor Sprint ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

30% Significant Relative Risk Reduction in Cardiac Death/MI

ENDEAVOR IV at 5 Years



p-Values were calculated by logrank test. *p*-Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV was not specifically designed or powered to individually compare CD/MI. RRR = relative risk reduction




Endeavor[®] Sprint

ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

Taxus DES vs ION DES

Same Drug, Same Polymer, Same Potential Results



ION DES: New Platform, Same Drug and Polymer

It's Still a Taxus Stent

		Taxus Liberté® DES	ION (Taxus Element) DES
Same	Drug	Paclitaxel	
	Polymer	SIBS (hydrophobic)	
	Drug elution profile	90% of the drug never elutes	
Different	Platform	Liberté	Element
	Platform material	Stainless steel	Platinum chromium
	Delivery system	Maverick 2	ION delivery system

Taxus Liberté DES



ION (Taxus Element) DES






Endeavor[®] Sprint


ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

ENDEAVOR Pooled Is Consistent with ENDEAVOR IV



Endeavor Demonstrates a Significant TLR Reduction in Pooled Analysis

ENDEAVOR Pooled vs. Driver BMS at 5 Years




Pooled data used for analysis: E I 5-yr, E II 5-yr, E II CA 5-yr, E III 5-yr, E IV 5-yr, E pK 5-yr.

Driver data came from ENDEAVOR II.

Values were calculated by logrank test. p -Values for outcome differences are unadjusted for multiple comparisons.

0.3% ARC definite/probable VLST in more than 1000 patients to 5 years

ENDEAVOR Pooled vs. Driver BMS: ARC Definite/Probable ST at 5 Years




Pooled data used for analysis: E I 5-yr, E II 5-yr, E II CA 5-yr, E III 5-yr, E IV 5-yr, E pK 5-yr.

Driver data came from ENDEAVOR II.

Values were calculated by logrank test. p -Values for outcome differences are unadjusted for multiple comparisons.

Significant Reduction in CD/MI vs. BMS at 5 Years in Pooled Analysis

ENDEAVOR Pooled vs. Driver BMS at 5 Years



Pooled data used for analysis: E I 5-yr, E II 5-yr, E II CA 5-yr, E III 5-yr, E IV 5-yr, E pK 5-yr. Driver data came from ENDEAVOR II. *p*-Values were calculated by logrank test. *p*-Values for outcome differences are unadjusted for multiple comparisons.

ENDEAVOR IV and ENDEAVOR Pooled Results at 5 Years

ENDEAVOR IV

- **Statistically significant difference in safety event rates for Endeavor DES vs. Taxus[®] DES**
 - 78% significant relative risk reduction in ARC definite/probable VLST ($p = 0.012$)
 - 30% significant relative risk reduction in CD/MI ($p = 0.048$)
- **TLR catch-up with Taxus DES leads to similar TLR**
 - 161% Increase with Taxus DES vs. only 71% TLR Increase with Endeavor DES from 1 to 5 years

ENDEAVOR Pooled

- **Low ENDEAVOR Pooled composite and component event rates**

p-Values were calculated by logrank test.

ENDEAVOR IV primary endpoint: noninferiority of Endeavor DES to Taxus DES at 9 months (target vessel failure).

ENDEAVOR IV was not specifically designed or powered to individually compare TLR, CD/MI or VLST.

p-Values for outcome differences are unadjusted for multiple comparisons.

www.medtronic.com
www.medtronicstents.com

Europe

Medtronic Intl. Trading SARL

Route du Molliau 31
Case Postale
CH-1131 Tolochenaz
Switzerland
Tel: +(41) 21.802.70.00
Fax: +(41) 21.802.79.00

Asia Pacific

Medtronic Intl. Ltd.

16/F Manulife Plaza
The Lee Gardens
33 Hysan Avenue
Causeway Bay
Hong Kong
Tel: +(852) 2919.1300
Fax: +(852) 2891.6830
enquiryap@medtronic.com

Canada

Medtronic of Canada Ltd.

99 Hereford Street
Brampton, Ontario L6Y 0R3
Canada
Tel: +1 (905) 460.3800
Fax: +1 (905) 460.3998
Toll-free: 1 (800) 268.5346

Latin America

Medtronic USA, Inc.


Doral Corporate Center II
3750 NW 87th Avenue
Suite 700
Miami, FL 33178
USA
Tel: +1 (305) 500.9328
Fax: +1 (786) 709.4244



Endeavor[®] Sprint

ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM


Appendix



ENDEAVOR IV: 5-Year Follow-Up

Clinical Trial Design


Principal Investigators: Martin B. Leon, MD, and David E. Kandzari, MD



Primary endpoint: TVF at 9 months
Secondary endpoints: In-segment % DS at 8 months
TLR and TVR at 9 months
Drug therapy: ASA and clopidogrel/Ticlid® ≥ 6 months
Zotarolimus dose: 10 µg per mm stent length

ENDEAVOR IV


Cumulative Incidence of ARC ST Definite/Probable to 5 Years



p -Values were calculated by logrank test. p -Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV was not specifically designed or powered to individually compare ST. RRR = relative risk reduction

ENDEAVOR IV


Cumulative Incidence of TLF to 5 Years



p-Value was calculated by logrank test. *p*-Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV was not specifically designed or powered to individually compare TLF.

45% Observed Relative Risk Reduction at 5 Years in TLR between 2 and 5 Years


ENDEAVOR IV at 5 Years



p-Value was calculated by logrank test. *p*-Values for outcome differences are unadjusted for multiple comparisons. ENDEAVOR IV was not specifically designed or powered to individually compare TLR. RRR = relative risk reduction

Excellent Safety Despite Only 39% of Endeavor Patients on DAPT at 1 Year

ENDEAVOR Pooled DAPT Compliance




1. Protocol requirement

The optimal duration of dual antiplatelet therapy, specifically clopidogrel, is unknown and DES thrombosis may still occur despite continued therapy. DAPT usage based on case report forms and reported at the time points shown. Trend line is for illustrative purposes only and does not represent continuous reporting.

Clinical Performance at 5 Years

ENDEAVOR IV Endpoints



p-Values for outcome differences are unadjusted for multiple comparisons.

p-Values were calculated by Fisher's exact test.

ENDEAVOR IV was not specifically designed or powered to individually compare TLR, MI, CD/MI or VLST.